Skip Navigation

DRUG RECORD

 

ZALEPLON

OVERVIEW
Zaleplon

 

Introduction

Zaleplon is a benzodiazepine receptor agonist and hypnotic that is used as a sleeping pill.  Zaleplon has not been implicated in causing serum enzyme elevations or clinically apparent liver injury.

 

Background

Zaleplon (zal' e plon) is a non-benzodiazepine, benzodiazepine receptor agonist of the pyrazolopyrimide class that acts by binding to the benzodiazepine (BZ) site on the GABA receptor complex, causing neural inhibition and helping to induce sleep.  Zaleplon has selectivity for certain BZ receptor subtypes and does not have the neuromuscular relaxation or anticonvulsant effects of the standard benzodiazepines.  Zaleplon has a short half life and rapid onset of action.  In multiple placebo-controlled trials, zaleplon was shown to decrease the latency to onset of sleep and improve perceived sleep quality with few next day residual effects and little evidence of rebound insomnia after withdrawal.  Zaleplon was approved for use in the United States in 1999 for the short term treatment of insomnia and it remains in wide use.  Zaleplon is available in 5 and 10 mg capsules generically and under the brand name Sonata.  The recommended dose is one 5 or 10 mg tablet taken orally immediately before bedtime.  Like the other benzodiazepine receptor agonists, zaleplon is classified as a Schedule IV controlled substance (low potential for abuse and limited physical or psychological dependence).  Side effects are uncommon, usually mild and may include headache, nausea, dizziness and drowsiness.

 

Hepatotoxicity

In multiple premarketing randomized controlled trials, zaleplon was not associated with an increased rate of serum enzyme elevations in comparison to placebo therapy, and no instance of clinically apparent liver injury was reported.  Since its approval and widescale use, zaleplon has not been implicated in causing clinically apparent liver disease.  Nevertheless, zaleplon is metabolized in the liver by the cytochrome P450 system (predominantly CYP 3A4) and can cause drug-drug interactions, although such interactions appear to be rare.  Thus, zaleplon induced liver injury must be exceedingly rare, if it occurs at all.

 

Drug Class:  Sedatives and Hypnotics

 

Other Drugs in the Subclass, Benzodiazepine Receptor Agonists:  Eszopiclone, Zolpidem

 

Top of page


 

REPRESENTATIVE TRADE NAMES
Zaleplon – Generic, Sonata®

 

DRUG CLASS
Sedatives and Hypnotics

 

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page


DRUG CAS REGISTRY NUMBER MOLECULAR FORMULA STRUCTURE
Zaleplon 151319-34-5 C17-H15-N5-O Zaleplon Chemical Structure

Top of page


REFERENCES
Zaleplon

 

References updated: 01 January 2015

 

  1. Zimmerman HJ. Anxiolytic agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 491-3.  (Expert review of hepatotoxicity published in 1999 discusses benzodiazepines and minor tranquilizers, but not the benzodiazepine receptor agonists; "In general, the hepatotoxic potential of this widely used group of compounds seems low").

  2. Larrey D, Ripault MP. Anxiolytic agents. Hepatotoxicity of psychotropic drugs and drugs of abuse. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, p. 455-6.  (Review of hepatotoxicity of hypnotics and sedatives discusses benzodiazepines, buspirone and valerian all of which have been linked to rare cases of liver injury; no discussion of zaleplon).

  3. Mihic SJ, Harris RA. Hypnotics and sedatives. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 457-80.  (Textbook of pharmacology and therapeutics).

  4. Israel AG, Kramer JA. Safety of zaleplon in the treatment of insomnia. Ann Pharmacother 2002; 36: 852-9. PubMed Citation  (Review of side effects and safety of both short and long term use of zaleplon in treatment of insomnia; no mention of ALT elevations or clinically apparent liver injury).

  5. Roblin X, Boudemaghe T, Paris F, Pellissier L, Le Gall S. [Unexplained increase in aminotransferases and obstructive sleep apnea syndrome]. Gastroenterol Clin Biol 2002; 26: 416-7. French. PubMed Citation  (45 year old woman found to have minor serum ALT elevations [1.5-3 times ULN] without jaundice or symptoms while taking zolpidem, which improved on stopping, but which were subsequently shown to be due to severe sleep apnea).

  6. Moore KA, Zemrus TL, Ramcharitar V, Levine B, Fowler DR. Mixed drug intoxication involving zaleplon ("Sonata"). Forensic Sci Int 2003; 134: 120-2. PubMed Citation  (41 year old woman died of overdose of multiple agents including zaleplon; liver histology not mentioned).

  7. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004; 43: 227-38. PubMed Citation  (Review of mechanism of action, pharmacology, efficacy and adverse effects of 3 non-benzodiazepine hypnotic agents: zaleplon, zolpidem and zopiclone).

  8. Drugs for insomnia. Treat Guidel Med Lett 2012; 10 (119): 57-60. PubMed Citation  (Guidelines for therapy of insomnia; mentions that benzodiazepine receptor agonists such as zaleplon, benzodiazepines, ramelteon and low doses of doxepin are effective and generally safe; in discussing adverse events, makes no mention of ALT elevations or hepatotoxicity of any of the recommended agents).

Top of page

 

OTHER REFERENCE LINKS
Zaleplon

 

  1. PubMed logoRecent References on Zaleplon

  2. Clinical Trials logoTrials on Zaleplon

Top of page